FI944821A - Galantaminderivat, förfarande för framställning av dessa och användning av dessa i läkemedel - Google Patents

Galantaminderivat, förfarande för framställning av dessa och användning av dessa i läkemedel Download PDF

Info

Publication number
FI944821A
FI944821A FI944821A FI944821A FI944821A FI 944821 A FI944821 A FI 944821A FI 944821 A FI944821 A FI 944821A FI 944821 A FI944821 A FI 944821A FI 944821 A FI944821 A FI 944821A
Authority
FI
Finland
Prior art keywords
hydrogen
drugs
preparation
alkylaminocarbonyl
alkyl
Prior art date
Application number
FI944821A
Other languages
English (en)
Finnish (fi)
Other versions
FI944821A0 (sv
FI108723B (sv
Inventor
Jr Raymond J Kosley
Larry Davis
Veronica Taberna
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of FI944821A0 publication Critical patent/FI944821A0/sv
Publication of FI944821A publication Critical patent/FI944821A/sv
Application granted granted Critical
Publication of FI108723B publication Critical patent/FI108723B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI944821A 1993-10-15 1994-10-13 Förfarande för framställning av 6-esterderivat av terapeutiskt avändbara 4a,5,9,10,11,12-hexahydro-11-metyl-6H-bensofuro[3a,3,2-ef][2]bensazepin-3,6-diol FI108723B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/137,440 US6323195B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors
US13744093 1993-10-15

Publications (3)

Publication Number Publication Date
FI944821A0 FI944821A0 (sv) 1994-10-13
FI944821A true FI944821A (sv) 1995-04-16
FI108723B FI108723B (sv) 2002-03-15

Family

ID=22477446

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944821A FI108723B (sv) 1993-10-15 1994-10-13 Förfarande för framställning av 6-esterderivat av terapeutiskt avändbara 4a,5,9,10,11,12-hexahydro-11-metyl-6H-bensofuro[3a,3,2-ef][2]bensazepin-3,6-diol

Country Status (23)

Country Link
US (2) US6323195B1 (sv)
EP (2) EP0653427B1 (sv)
JP (1) JP2664344B2 (sv)
KR (1) KR0169114B1 (sv)
CN (1) CN1039911C (sv)
AT (1) ATE212348T1 (sv)
AU (1) AU696249B2 (sv)
CA (1) CA2118174C (sv)
CZ (1) CZ287071B6 (sv)
DE (1) DE69429708T2 (sv)
DK (1) DK0653427T3 (sv)
EG (1) EG20472A (sv)
ES (1) ES2171428T3 (sv)
FI (1) FI108723B (sv)
IL (1) IL111274A (sv)
NO (1) NO310415B1 (sv)
NZ (1) NZ264683A (sv)
PL (1) PL177730B1 (sv)
PT (1) PT653427E (sv)
RO (1) RO114133B1 (sv)
RU (1) RU2114850C1 (sv)
TW (1) TW363969B (sv)
ZA (1) ZA948062B (sv)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP2311441A1 (en) * 1998-11-23 2011-04-20 Bonnie M. Davis Dosage formulations for acetylcholinesterase inhibitors
ES2211215T3 (es) 1998-12-24 2004-07-01 Janssen Pharmaceutica N.V. Composicion de galantamina de liberacion controlada.
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
WO2000041540A2 (en) * 1999-01-11 2000-07-20 Atanas Russinov Djananov Herbal supplement for increased muscle strength and endurance for athletes
DE69913138T2 (de) * 1999-03-31 2004-08-26 Eisai Co., Ltd. Stabilisierte zusammensetzung mit nootropen wirkstoffen
CA2388830C (en) * 1999-10-26 2006-09-19 Janssen Pharmaceutica N.V. Oral solution containing galanthamine and a sweetening agent
MXPA02005667A (es) * 1999-12-10 2004-09-10 Bonnie Davis Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos.
ES2215885T3 (es) 2000-03-31 2004-10-16 Sanochemia Pharmazeutika Aktiengesellschaft Nuevos derivados y analogos de la galantamina.
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
US20060257461A1 (en) * 2005-05-13 2006-11-16 Jansen Rolf R Multilayer galantamine delivery system with barrier against reservoir material flow
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
ATE473219T1 (de) * 2005-09-22 2010-07-15 Galantos Pharma Gmbh Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
EP1777222A1 (en) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
ES2463715T3 (es) 2008-04-14 2014-05-29 Neurodyn Life Sciences Inc. Derivados de galantamina como profármacos para el tratamiento de enfermedades del cerebro humano
CA2768668A1 (en) * 2009-07-23 2011-01-27 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
EP3628315A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
CN113292420A (zh) * 2021-05-27 2021-08-24 神隆医药(常熟)有限公司 加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3856594D1 (de) * 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
US5312817A (en) 1991-05-14 1994-05-17 Ernir Snorrason Treatment of fatigue syndrome
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
RO114133B1 (ro) 1999-01-29
FI944821A0 (sv) 1994-10-13
US5777108A (en) 1998-07-07
FI108723B (sv) 2002-03-15
CA2118174A1 (en) 1995-04-16
ZA948062B (en) 1995-06-06
KR950011443A (ko) 1995-05-15
ES2171428T3 (es) 2002-09-16
US6323195B1 (en) 2001-11-27
JP2664344B2 (ja) 1997-10-15
EP1020470A2 (en) 2000-07-19
RU94036448A (ru) 1996-09-10
EP0653427A1 (en) 1995-05-17
CN1039911C (zh) 1998-09-23
IL111274A (en) 2000-11-21
CZ254694A3 (en) 1995-09-13
PL305456A1 (en) 1995-04-18
DE69429708D1 (de) 2002-03-14
RU2114850C1 (ru) 1998-07-10
NO310415B1 (no) 2001-07-02
PL177730B1 (pl) 2000-01-31
EP1020470A3 (en) 2000-07-26
AU7581494A (en) 1995-05-04
DK0653427T3 (da) 2002-04-15
TW363969B (en) 1999-07-11
CZ287071B6 (en) 2000-08-16
NO943893D0 (no) 1994-10-14
EG20472A (en) 1999-05-31
NZ264683A (en) 1998-03-25
NO943893L (no) 1995-04-18
ATE212348T1 (de) 2002-02-15
AU696249B2 (en) 1998-09-03
EP0653427B1 (en) 2002-01-23
KR0169114B1 (ko) 1999-01-15
CA2118174C (en) 2000-01-18
JPH07188240A (ja) 1995-07-25
CN1111245A (zh) 1995-11-08
PT653427E (pt) 2002-06-28
DE69429708T2 (de) 2002-08-29
IL111274A0 (en) 1994-12-29

Similar Documents

Publication Publication Date Title
FI944821A (sv) Galantaminderivat, förfarande för framställning av dessa och användning av dessa i läkemedel
CA2092794A1 (fr) Naphtylalkylamines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MY131501A (en) Process for the prepration of clavulanic acid
CA2075876A1 (fr) Nouveaux derives d'arylethylamines, leurs procedes de preparation et lescompositions pharmaceutiques qui les contiennent
FI944822A0 (sv) Galantaminderivat, förfarande för framställning av dessa och användning av dessa i läkemedel
IL110151A0 (en) Amide and urea derivatives and pharmaceutical compositions containing the same
FI103046B1 (sv) Förfarande för framställning av som läkemedel användbara pyrrolidinyltiokarbapenemderivater
DK0628042T3 (da) Serotoninerge ergolinderivater
NO953557L (no) Antitumorpreparater og fremgangsmåte for deres fremstilling
GB2282810A (en) Process for the preparation of clavulanic acid

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: HOECHST MARION ROUSSEL, INC.

PC Transfer of assignment of patent

Owner name: AVENTISUB II INC.

Free format text: AVENTISUB II INC.

MA Patent expired